U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07099898) titled 'A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)' on July 30.
Brief Summary: "In this study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared ...